Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.06 USD

41.06
1,724,263

+0.74 (1.84%)

Updated Aug 13, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

by Zacks Equity Research

AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.

Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%

by Zacks Equity Research

Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

by Zacks Equity Research

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use

by Zacks Equity Research

J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

by Zacks Equity Research

Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab

by Zacks Equity Research

Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.

GSK PLC Sponsored ADR (GSK) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Zacks Analyst Blog Highlights Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods, GlaxoSmithKline and Toyota Motor.

by Zacks Equity Research

Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods, GlaxoSmithKline and Toyota Motor are part of the Zacks top Analyst Blog.

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

by Zacks Equity Research

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Nalak Das headshot

Inflation Remains Sticky in February: 5 Safe Picks

by Nalak Das

We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.

Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study

by Zacks Equity Research

Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.

Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

by Zacks Equity Research

Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

by Zacks Equity Research

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab

by Zacks Equity Research

The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

by Zacks Equity Research

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Sheraz Mian headshot

Top Research Reports for Adobe, United Parcel & Deere

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), United Parcel Service, Inc. (UPS) and Deere & Company (DE).

Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.